Parenteral neonatal priming followed by heterologous mucosal booster favors IgM+ memory B cell induction over systemic plasma cell differentiation - Takeaways - MDSpire

Parenteral neonatal priming followed by heterologous mucosal booster favors IgM+ memory B cell induction over systemic plasma cell differentiation

  • By

  • Poorya Foroutan Pajoohian

  • Audur Anna Aradottir Pind

  • Jenny Lorena Molina Estupiñan

  • Dennis Christensen

  • Gabriel Kristian Pedersen

  • Thorunn A. Olafsdottir

  • Ingileif Jonsdottir

  • Stefania P. Bjarnarson

  • May 5, 2026

  • 0 min

Share

  • 1

    Early-life vaccinations often result in short-lived antibody responses due to limited germinal center activity and plasma cell survival.

  • 2

    The study assessed how homologous versus heterologous vaccine delivery routes influence early-life germinal center dynamics and memory B cell development.

  • 3

    Heterologous subcutaneous/intranasal immunization preferentially generated IgM+ memory B cells, while homologous subcutaneous immunization promoted plasma cell differentiation.

  • 4

    The anatomical site of germinal center responses was determined by the booster immunization route, affecting systemic and mucosal antibody responses.

  • 5

    These findings support the design of early-life vaccines that enhance either systemic IgG or combined systemic-mucosal antibody responses.

Original Source(s)

Parenteral neonatal priming followed by heterologous mucosal booster favors IgM+ memory B cell induction over systemic plasma cell differentiation

  • by Poorya Foroutan Pajoohian, Audur Anna Aradottir Pind, Jenny Lorena Molina Estupiñan, Dennis Christensen, Gabriel Kristian Pedersen, Thorunn A. Olafsdottir, Ingileif Jonsdottir, Stefania P. Bjarnarson

  • May 5, 2026

Related Content

Beyond Women's Health: Long-Term Human Papillomavirus–Related Cancer Trends in Norway

Clinical Characteristics of Tick-Borne Encephalitis in Adult Patients: A 10-year Retrospective Study in Stockholm, Sweden

Models of autoantibody mediated diseases: actively nearing the human gold standard